200
Participants
Start Date
May 16, 2025
Primary Completion Date
April 23, 2031
Study Completion Date
April 23, 2031
YL201
YL201 will be administered as an IV infusion.
Tarlatamab
Tarlatamab will be administered as an IV infusion.
Atezolizumab
Atezolizumab will be administered as an IV infusion.
Durvalumab
Durvalumab will be administered as an IV infusion.
RECRUITING
Moffitt Cancer Center, Tampa
RECRUITING
Sanford Oncology Clinic and Pharmacy, Sioux Falls
RECRUITING
Sanford Roger Maris Cancer Center, Fargo
RECRUITING
Siteman Cancer Center, St Louis
RECRUITING
University of Texas MD Anderson Cancer Center, Houston
RECRUITING
City of Hope Orange County Lennar Foundation Cancer Center, Irvine
RECRUITING
Swedish Medical Center, Seattle
RECRUITING
Shandong Cancer Hospital, Jinan
RECRUITING
Fujian Cancer Hospital, Fuzhou
RECRUITING
West China Hospital of Sichuan University, Chengdu
RECRUITING
Yale New Haven Hospital, New Haven
RECRUITING
Dana Farber Cancer Institute, Boston
RECRUITING
CHU de Quebec Hopital de l Enfant Jesus, Québec
RECRUITING
Severance Hospital Yonsei University Health System, Seoul
RECRUITING
Asan Medical Center, Seoul